4basebio (LON:4BB) Stock Price Down 1.5% – Should You Sell?

4basebio PLC (LON:4BB)’s stock price dropped 1.5% on Tuesday . The company traded as low as GBX 606 and last traded at GBX 606. Approximately 3 shares were traded during trading, a decline of 100% from the average daily volume of 1,223 shares. The stock had previously closed at GBX 615.

Analysts Set New Price Targets

Separately, Royal Bank Of Canada reiterated an “outperform” rating and issued a GBX 1,600 target price on shares of 4basebio in a research report on Thursday, October 2nd. One investment analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, 4basebio has an average rating of “Buy” and an average target price of GBX 1,600.

4basebio Stock Performance

The company has a debt-to-equity ratio of 201.47, a current ratio of 2.73 and a quick ratio of 3.52. The company has a market capitalization of £93.84 million, a PE ratio of -6.12 and a beta of 1.09. The stock has a 50-day simple moving average of GBX 701.37 and a 200 day simple moving average of GBX 824.48.

4basebio (LON:4BB) last released its quarterly earnings results on Monday, September 29th. The company reported GBX (50) earnings per share (EPS) for the quarter. Equities analysts anticipate that 4basebio PLC will post -3.43 EPS for the current fiscal year.

About 4basebio

4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients.

Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients. These products and technologies are also available for customers and partners with whom we endeavor to combine our capabilities and know-how to develop gene therapy solutions for clinical development and commercialisation.